Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurocrine Biosciences Inc.

www.neurocrine.com

Latest From Neurocrine Biosciences Inc.

Deal Watch: AstraZeneca Continues Divestments By Offloading US/Canada Seroquel Rights

Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.

Deals Business Strategies

Neurocrine Adds Epilepsy Assets From Xenon

Neurocrine plans to advance XEN901 into Phase II in a rare pediatric epilepsy indication while eyeing opportunity in adult focal epilepsy. Xenon increases its runway to develop a pair of mid-stage epilepsy drugs.

Business Strategies Deals

Parkinson’s Disease: Novel Science And Collaborations Fuel Progress

Novel therapeutic strategies for Parkinson’s disease have brought a renewed sense of optimism to those researching this neurodegenerative disorder. Numerous treatment avenues are being explored, including small molecules, gene therapy, cell therapy and medical devices to stimulate nerves deep in the brain. Digital also gets a look-in, being useful for analyzing gait and other symptoms, and addressing both mental and physical issues.

BioPharmaceutical Neurology

ObsEva Gives Up On IVF Drug As Phase III Study Fails

Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.

Clinical Trials Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gynecological, Urological
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Neurocrine Biosciences Inc.
  • Senior Management
  • Kevin C Gorman, PhD, CEO
    Kyle Gano, PhD, Chief Bus. Dev. Officer
    Haig Bozigian, PhD, Chief Dev. Officer
    Dimitri Grigoriadis, PhD, Chief Research Officer
    Malcolm Lloyd-Smith , Chief Reg. Officer
    Christopher O'Brien, MD, CMO
  • Contact Info
  • Neurocrine Biosciences Inc.
    Phone: (858) 617-7600
    12780 El Camino Real
    San Diego, CA 92130
    USA
UsernamePublicRestriction

Register